Unknown

Dataset Information

Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model.


ABSTRACT:

Introduction

There is an urgent clinical need to accurately predict the risk for disease progression in post-treatment NSCLC patients, yet current ctDNA mutation profiling approaches are limited by low sensitivity. We represent a non-invasive liquid biopsy assay utilizing cfDNA neomer profiling for predicting disease progression in 44 inoperable localized NSCLC patients.

Methods

A total of 97 plasma samples were collected at various time points during or post-treatments (TP1: 39, TP2: 33, TP3: 25). cfDNA neomer profiling, generated based on target sequencing data, was used to fit survival support vector machine models for each time point. Leave-one-out cross-validation (LOOCV) was performed to evaluate the models' predictive performances.

Results

Our cfDNA neomer prof

SUBMITTER: Wu Y 

PROVIDER: S-EPMC11499892 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature